Genzyme in Europe: The Moment of Truth
Genzyme has long had a presence in Europe, but it now faces its most public challenges. With Fabrazyme having to share its orphan drug exclusivity, and sales of key growth-driver Renagel below expectations, the US firm is finding that although experience helps, it doesn't guarantee a leading market share.
You may also be interested in...
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?
It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.